Sector News

After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact

February 14, 2021
Life sciences

Last year, AbbVie decided to walk away from a pact with gene editing biotech Editas that was originally penned via its new buyout, Allergan.

Now, the Big Pharma is back in the CRISPR biotech game, signing up to a new deal with Editas’ rival Caribou Biosciences, although this research deal goes further.

AbbVie is tapping Caribou’s CRISPR genome editing platform to engineer CAR-T cells to withstand the so-called host immune attack, which would enable the development of the next generation of “off-the-shelf” cellular therapies to benefit a broader patient population. These would also be quicker and easier than traditional CAR-T therapies to make and use.

Its original deal with Editas, via Allergan, was made in 2017 and was worth $90 million for a CRISPR research pact that focused on ocular disorders but not on CAR-T.

AbbVie clearly had other plans, canning that deal in August last year and choosing Caribou instead. The deal sees just $40 million go to the biotech upfront, with a modest $300 million in biobucks also on the table as well as royalties should any treatments grab approvals.

The pact will see AbbVie use Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy tech to research and develop two new CAR-T cell therapies directed to targets “specified by AbbVie,” though not in its release, which was light on target details; most CAR-Ts, however, are being directed against common forms of blood cancer.

Caribou, meanwhile, will conduct certain preclinical research, development and manufacturing activities for the collab programs, and AbbVie will reimburse Caribou for its efforts. AbbVie also holds on to an option to pay a fee to expand the pact to include up to an additional two CAR-T cell therapies.

by Ben Adams

Source: fiercebiotech.com

Related News

June 19, 2021

P&G-backed Kindra to tap into overlooked menopause sector after landing US$4.5M

Life sciences

Kindra has closed a US$4.5 million seed funding round to expand and grow its menopause offerings. The US-based brand, which is backed by P&G Ventures, aims to drive a cultural shift around menopause, which has been “long overlooked.”

June 19, 2021

Johnson & Johnson among companies excluding Colorado residents from remote job openings after new state law

Life sciences

Colorado established a new law this year requiring companies to divulge a salary range on job postings. But some large companies, like Johnson & Johnson, McKesson and Cardinal Health, have responded by barring candidates from the state.

June 19, 2021

Former Emisphere investors sue over ‘ill-timed’ $1.8B sale to Novo Nordisk

Life sciences

Former Emisphere stockholder IsZo Capital is one of several parties seeking damages against controlling stockholder MHR Fund Management for allegedly “co-opting” the drug delivery specialist’s board and forcing an “ill-timed” sale to Novo Nordisk at an “artificially low price,” a new lawsuit says.

Send this to a friend